Navigation Links
Plan-Neofluar

ProductsPlan-Neofluar
Company Carl Zeiss MicroImaging, Inc.
Item Plan-Neofluar
Features Inquire
Description Plan-Neofluar objectives feature full monochromatic and chromatic correction for the focal plane, high resolving power and brilliant, rich-contrast, completely flat images for observation and photomicrography by all transmitted-light methods. Their high transmission of wavelengths up to the near UV range (360 nm) and the use of glass types of low autofluorescence makes these objectives ideal for epi-fluorescence microscopy.
The Plan-Neofluar family includes multi-immersion objectives of high numerical aperture - another advantage for epi-fluorescence.
Info Carl Zeiss MicroImaging, Inc.
Customer Service: (800) 233-2343
Web site: http://www.zeiss.com/micro

Related medicine products :

1. Plan-Neofluar objectives
2. Plan-Neofluar Antiflex
Modular Specimen Filing System has five cells that can hold either slides or tissue cassettes....
Shandon Microscope Slide Cabinet with Drawers...
... is the first solid-state,photocoagulator to ... wavelengths. This advanced,laser system makes ... a red or green wavelength,during ... and ensures effective,patient results., For ...
... The PSL utilizes a high luminance white LED ... lightweight, compact design, to give you the freedom ... The PSL Slit Lamp weighs only about 1.5 ... easily and comfortably in your hand. Its ...
Medicine Products:
(Date:12/17/2009)... Helped, Healed, and Preserved Good Health , ... ... Association (IHRSA) announced today that as part of its Campaign for ... abilities to make 2010 the year we unite in a national ... daily exercise is highly valued and widely practiced. IHRSA is inviting ...
(Date:12/17/2009)... , , THURSDAY, Dec. 17 (HealthDay News) -- Among teenage ... least one of three common sexually transmitted infections -- ... becoming sexually active, a new study has found. , ... also found that it was common for these patients ... within four to six months after treatment of the ...
(Date:12/17/2009)... of Science in Human Resource Development Degree Online , ... ... -- Open enrollment has begun for Villanova’s newly online ... professionals whose busy schedules can’t accommodate a campus-based program. With ... online in March 2010, location is no longer a barrier ...
(Date:12/17/2009)... SAN DIEGO, Dec. 17 Neurocrine Biosciences, Inc. ... entered into a privately negotiated transaction to sell an ... to affiliates of Venrock at a price of $2.09 ... approximately $10 million. Neurocrine expects the financing to close ... closing conditions. ,, A shelf registration statement ...
(Date:12/17/2009)... Procedure Provides Efficient Mechanism to Pursue Approval ... Dec. 17 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: ... it has initiated the regulatory approval process ... under the Decentralized Procedure (DCP). The DCP ... company to simultaneously pursue regulatory approval for ...
Breaking Medicine News(10 mins):Health News:IHRSA's Campaign for a Healthier America Calls on All Americans to Curtail Health Care Costs in 2010 by Becoming Physically Active 2Health News:IHRSA's Campaign for a Healthier America Calls on All Americans to Curtail Health Care Costs in 2010 by Becoming Physically Active 3Health News:IHRSA's Campaign for a Healthier America Calls on All Americans to Curtail Health Care Costs in 2010 by Becoming Physically Active 4Health News:IHRSA's Campaign for a Healthier America Calls on All Americans to Curtail Health Care Costs in 2010 by Becoming Physically Active 5Health News:STDs Common Among Sexually Active Teen Girls in Cities 2Health News:A World-Class HR Master's Degree Is Now Within Reach – 100% Online 2Health News:A World-Class HR Master's Degree Is Now Within Reach – 100% Online 3Health News:Neurocrine Announces Sale of 4,784,689 Shares of Common Stock, to Raise Proceeds of $10 Million 2Health News:Neurocrine Announces Sale of 4,784,689 Shares of Common Stock, to Raise Proceeds of $10 Million 3Health News:Labopharm Initiates Regulatory Approval Process for Twice-Daily Tramadol-Acetaminophen in Europe 2Health News:Labopharm Initiates Regulatory Approval Process for Twice-Daily Tramadol-Acetaminophen in Europe 3
... AARP asks,Governor Schwarzenegger to fight on behalf ... the State Children,s Health,Insurance Program (SCHIP). The U.S. ... and extend SCHIP, covering millions of low-income,uninsured children ... to veto,any bill that would expand the program ...
... National Board of Medical,Examiners is appealing the decision ... which granted the petition of breastfeeding,mother Sophie Currier ... "Our overriding concerns are fairness to all examinees ... an important gateway to medical,practice," said Joseph F. ...
... exclusive North American rights to bepotastine for nasal ... ... 26 ISTA,Pharmaceuticals, Inc. (Nasdaq: ISTA ), announced today it ... an,investigational product for the treatment of allergy symptoms, from Tanabe,Seiyaku Co., ...
... Offers Families Information, Access to Experts and Advice on how to ... Navigate Health Care System ... Speaker, NEW YORK, Sept. 26 Nearly 10 million women,and one ... yet to be clinically identified and treated. How does,one identify an eating ...
... the fall season has,officially begun, the need to protect four-legged ... original,online home of animal health news, offers pet owners these ... -- Fleas are the most common external parasite in cats ... humid environments and feed on the blood of their ...
... to the National,Breast Cancer Foundation, nearly 200,000 women will ... lives, and while it is,widely known that a mammogram ... of women either can,t afford to receive testing or ... to mammograms for,women in underserved communities, Colgate-Palmolive (NYSE: ...
Other Medicine News:Health News:AARP Calls on Governor Schwarzenegger to Discourage Veto of SCHIP Expansion Bill 2Health News:ISTA Pharmaceuticals Expands Its Pipeline in Allergy Treatments 2Health News:ISTA Pharmaceuticals Expands Its Pipeline in Allergy Treatments 3Health News:ISTA Pharmaceuticals Expands Its Pipeline in Allergy Treatments 4Health News:ISTA Pharmaceuticals Expands Its Pipeline in Allergy Treatments 5Health News:Does your Child or Spouse have an Eating Disorder? If They Did, Would You Know? 2Health News:Summer Temperatures Linger, Extend Threat of Parasites 2Health News:Colgate-Palmolive Partners With the National Breast Cancer Foundation to Provide Education and Free Mammograms 2Health News:Colgate-Palmolive Partners With the National Breast Cancer Foundation to Provide Education and Free Mammograms 3
(Date:12/17/2009)... RALEIGH, N.C., Dec. 17 Pharmaceutical Institute ... from GeneEd, Inc., a company specializing in life ... advanced e-courses, help expand Pharmaceutical Institute,s already extensive ... Institute is a leading provider of specialized training ... a subsidiary of Campbell Alliance. Financial terms ...
(Date:12/17/2009)... PHOENIX, Dec. 17 The Make-A-Wish Foundation ... million donation from the LATISSE ® ... sponsored by Allergan, Inc. ,, Based on the ... a wish come true, the campaign launched earlier ... the Make-A-Wish Foundation by leveraging the excitement around ...
(Date:12/16/2009)... Cell Therapeutics, Inc. (CTI) (Nasdaq ... February 10, 2010 the U.S. Food and ... will review the New Drug Application (NDA) ... aggressive non-Hodgkin,s lymphoma (NHL). ODAC is an ... concerning the efficacy and safety of marketed ...
Breaking Medicine Technology:Pharmaceutical Institute Acquires E-Learning Assets from GeneEd, Inc. 2Pharmaceutical Institute Acquires E-Learning Assets from GeneEd, Inc. 3The Make-A-Wish Foundation(R) Receives $1 Million Donation from LATISSE(R) Wishes Campaign 2The Make-A-Wish Foundation(R) Receives $1 Million Donation from LATISSE(R) Wishes Campaign 3The Make-A-Wish Foundation(R) Receives $1 Million Donation from LATISSE(R) Wishes Campaign 4The Make-A-Wish Foundation(R) Receives $1 Million Donation from LATISSE(R) Wishes Campaign 5Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010 2Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010 3Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010 4Cambrex Reports Second Quarter 2009 Results 53671 1Cambrex Reports Second Quarter 2009 Results 53671 2Cambrex Reports Second Quarter 2009 Results 53671 3Cambrex Reports Second Quarter 2009 Results 53671 4Cambrex Reports Second Quarter 2009 Results 53671 5Cambrex Reports Second Quarter 2009 Results 53671 6Cambrex Reports Second Quarter 2009 Results 53671 7Cambrex Reports Second Quarter 2009 Results 53671 8Cambrex Reports Second Quarter 2009 Results 53671 9Cambrex Reports Second Quarter 2009 Results 53671 10Cambrex Reports Second Quarter 2009 Results 53671 11Cambrex Reports Second Quarter 2009 Results 53671 12Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Canaccord Adams Global Growth Conference in Boston on August 11 2009 53666 1Nektar Therapeutics Reports Second Quarter 2009 Financial Results 4824 1Nektar Therapeutics Reports Second Quarter 2009 Financial Results 4824 2Nektar Therapeutics Reports Second Quarter 2009 Financial Results 4824 3Nektar Therapeutics Reports Second Quarter 2009 Financial Results 4824 4Nektar Therapeutics Reports Second Quarter 2009 Financial Results 4824 5Nektar Therapeutics Reports Second Quarter 2009 Financial Results 4824 6Nektar Therapeutics Reports Second Quarter 2009 Financial Results 4824 7Nektar Therapeutics Reports Second Quarter 2009 Financial Results 4824 8Nektar Therapeutics Reports Second Quarter 2009 Financial Results 4824 9Nektar Therapeutics Reports Second Quarter 2009 Financial Results 4824 10